Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX)

6.23
Delayed Data
As of Jul 31
 +0.24 / +4.01%
Today’s Change
4.45
Today|||52-Week Range
7.78
+4.18%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$100.8M

Company Description

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company. It is focused on the acquisition, development and commercialization of branded prescription products. The company's primary target markets include hospital acute care and gastroenterology. Its product portfolio includes Acetadote injection for the treatment of acetaminophen poisoning; Caldolor injection for the treatment of pain and fever; Kristalose for oral solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and related duodenal ulcer disease; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren injection, a phase II candidate for the treatment of critically ill hospitalized patients suffering from liver and kidney failure associated with hepatorenal syndrome; and Boxaban oral capsules, a phase II candidate for the treatment of patients with aspirin-exacerbated respiratory disease. Cumberland Pharmaceuticals was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Contact Information

Cumberland Pharmaceuticals, Inc.
2525 West End Avenue
Nashville Tennessee 37203
P:(615) 255-0068
Investor Relations:

Employees

Shareholders

Mutual fund holders8.19%
Individual stakeholders45.87%
Other institutional25.20%

Top Executives

A. J. KazimiChairman & Chief Executive Officer
Leo PavlivChief Development Officer & Senior VP-Operations
Rick Scott GreeneChief Financial Officer, VP-Finance & Accounting
Amy Dix RockSenior Director-Regulatory & Scientific Affairs
Arthur P. WheelerDirector-Medical Affairs